Literature DB >> 16227636

Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor.

Eric D Tetzlaff1, Jaffer A Ajani.   

Abstract

Carcinoid tumors are rare and often resistant to chemotherapy agents. Although a slow-growing tumor, patients can have significant morbidity associated with carcinoid syndrome and patients will often die as a result of tumor progression. We report the first case of a patient with a metastatic carcinoid tumor to respond to an oxaliplatin-based regimen. Further studies are needed to validate this observation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16227636     DOI： 10.1385/IJGC:36:1:055

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN： 1537-3649


  14 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Carcinoids (Argentaffin-Cell Tumors) and Nerve Hyperplasia of the Appendicular Mucosa.

Authors:  P Masson
Journal:  Am J Pathol       Date:  1928-05       Impact factor: 4.307

3.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

Authors:  P Chollet; M A Bensmaïne; S Brienza; C Deloche; H Curé; H Caillet; E Cvitkovic
Journal:  Ann Oncol       Date:  1996-12       Impact factor: 32.976

Review 4.  Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

Authors:  D M Kweekel; H Gelderblom; H-J Guchelaar
Journal:  Cancer Treat Rev       Date:  2005-04       Impact factor: 12.111

5.  Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

Authors:  C Louvet; T André; J M Tigaud; E Gamelin; J Y Douillard; R Brunet; E François; J H Jacob; D Levoir; A Taamma; P Rougier; E Cvitkovic; A de Gramont
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

6.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

Authors:  D Machover; E Diaz-Rubio; A de Gramont; A Schilf; J J Gastiaburu; S Brienza; M Itzhaki; G Metzger; D N'Daw; J Vignoud; A Abad; E Francois; E Gamelin; M Marty; J Sastre; J F Seitz; M Ychou
Journal:  Ann Oncol       Date:  1996-01       Impact factor: 32.976

7.  A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.

Authors:  L Saltz; N Kemeny; G Schwartz; D Kelsen
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

8.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.

Authors:  I Monnet; S Brienza; F Hugret; S Voisin; J Gastiaburu; J C Saltiel; P Soulié; J P Armand; E Cvitkovic; H de Cremoux
Journal:  Eur J Cancer       Date:  1998-06       Impact factor: 9.162

9.  A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.

Authors:  F Lévi; J L Misset; S Brienza; R Adam; G Metzger; M Itzakhi; J P Caussanel; F Kunstlinger; S Lecouturier; A Descorps-Declère
Journal:  Cancer       Date:  1992-02-15       Impact factor: 6.860

Review 10.  Carcinoid--a comprehensive review.

Authors:  Isac I Schnirer; James C Yao; Jaffer A Ajani
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089
View more
  2 in total

1.  Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.

Authors:  Ikechukwu Akunyili; Monica T Garcia-Buitrago; Jessica Macintyre; Joe Levi; Caio M Rocha Lima
Journal:  J Gastrointest Oncol       Date:  2011-06

2.  Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.

Authors:  Marjorie Faure; Patricia Niccoli; Aurelie Autret; Gerard Cavaglione; Laurent Mineur; Jean-Luc Raoul
Journal:  Mol Clin Oncol       Date:  2016-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.